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Brief Report
Introduction
Hospital-acquired infections are a major contributor to 
inpatient morbidity, mortality, and health care costs. 
Ventilator-associated pneumonia (VAP) is among the 
most common. It is associated with longer duration of 
mechanical ventilation (MV), longer intensive care unit 
stays, increase in cost per case of VAP of at least $40 
000, and over 2-fold increased risk of mortality.1,2 
Hospital rates of VAP are subject to mandated reporting 
and measured against national benchmarks. However, 
because the definition of VAP is complex and includes 
subjective signs and symptoms, the reported incidence 
in children varies widely from 0.3 to 45.1 cases per 1000 
ventilator days.3 VAP may not include all clinically 
important infections associated with MV.4 Another 
infection, ventilator-associated tracheobronchitis (VAT), 
has been described using varying definitions with 
unclear clinical significance. The incidence of VAT in 
pediatric intensive care unit (PICU) populations has 
been reported at 3.4% to 7.3% of ventilated patients, and 
as high as 21.2% in trauma patients.5-9 VAT has been 
associated with longer duration of MV and length of 
stay but not increased mortality.5-7
Variable definitions have been used in studies of 
VAT, but generally include clinical signs of respiratory 
infection in the absence of pneumonia on chest radio-
graph combined with a positive respiratory culture.8,9 
Recent studies of VAT in pediatrics have all used a defi-
nition based on the Centers for Disease Control and 
Prevention/National Healthcare Safety Network (CDC/
NHSN) definition of “lower respiratory tract infection 
other than pneumonia” and applied it to children on 
MV.5-7,10 Definitions of VAT, and those of VAP, are com-
plicated by their reliance on poor interpretability and 
subjectivity of data including clinical signs and chest 
radiographs. Microbiologic testing is complicated due to 
the lack of standard microbiologic methods.3 Respiratory 
specimens can be obtained by bronchoscopic or non-
bronchoscopic bronchoalveolar lavage (BAL), by 
protected specimen brush, or by endotracheal aspirate 
(ETA) via new or inline suction catheters. ETA may be 
preferred due to perceived safety, feasibility, and cost 
concerns.4 However, validity of cultures obtained by 
ETA may be questioned due to bacterial colonization of 
endotracheal tubes. Quantitative bacterial cultures may 
improve specificity of ETA cultures for infection over 
colonization, and a threshold of >105 cfu/mL has been 
suggested.9 Publications on VAT have invariably used 
ETA as the method to obtain specimens, but have varied 
in the use of quantitative culture.
In our institution, BAL is used for the routine evalua-
tion of ventilator-associated infections including VAP 
and VAT. Surveillance cultures and ETA are not per-
formed due to concerns of interpretability of results. 
Because of this, we are in a unique position to provide 
the first report of BAL results in a large cohort of PICU 
patients. We hypothesized that VAP represents only a 
small portion of positive BALs, suggesting that other 
potentially significant ventilator-associated infections 
are not well characterized.
Methods
Setting and Patients
This study was performed in a 34-bed mixed medical-
surgical (including cardiac) PICU of a tertiary care 
children’s hospital. All BAL cultures ordered at the 
discretion of the bedside provider from patients 
ventilated for any reason during the study period were 
evaluated.
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Data Collection
Infection control practitioners maintained a prospective 
database of all BAL culture results for quality assurance 
and VAP monitoring and reporting. This de-identified 
database containing date of admission, date of culture, 
and culture results was retrospectively reviewed from 
January 1, 2011, to June 30, 2013. This was compared 
with institutionally collected data of reported VAPs, the 
number of ventilated patients, and MV days.
Definitions of Comparison Groups
CDC/NHSN definition of VAP was used for monitoring 
and reporting purposes.10 Any growth of pathogenic 
bacteria was defined as a positive BAL, and either no 
growth or growth of “normal flora” was defined as a 
negative BAL. Cultures done on the first or second day 
of admission were excluded in order to evaluate hospi-
tal-acquired infections versus those that were present on 
admission. The proportions of patients on MV with VAP 
or positive BAL were calculated. The rates of VAP and 
positive BAL were reported as number of events per 
1000 ventilator days. Comparisons were made using 
Fisher’s exact test.
BAL and Microbiological Methodology
BAL, obtained either by bronchoscopy or non- 
bronchoscopically, was routinely used to evaluate for 
suspected infection. Generally, most cultures are 
obtained non-bronchoscopically for routine gram stain 
and bacterial culture. Bronchoscopy is preferred only 
when larger volumes of aspirate are needed to run 
additional diagnostic testing (such as cultures for 
fungus or atypical infection), or when bronchoscopy is 
otherwise therapeutically indicated.
Non-bronchoscopic specimens are obtained using 
sterile technique by the respiratory therapist using a 
telescoping protected catheter (Combicath, KOL Bio-
Medical Instruments, Inc, Chantilly, VA). The catheter 
is wedged into the distal airway, and 0.5 mL/kg (up to 
20 mL) of saline is instilled into the airway and then 
aspirated. The microbiology laboratory reports the 
results of a gram stain semiquantitatively. The results of 
the bacterial culture are reported quantitatively, if pos-
sible, or semiquantitatively in the case of an inadequate 
sample size to perform quantitation.
Results
Over the 30-month study period, there were 2066 venti-
lated patients with 20 114 ventilator days. A total of 385 
BALs were sent, of which 115 were done on the first or 
second day of admission. Of the 270 BALs done beyond 
the second day of admission, 143 grew pathogenic bacte-
ria, which was 53% of BAL specimens. A positive BAL 
culture beyond the second day of admission occurred in 
6.92% of ventilated patients, with a rate of 7.11/1000 
ventilator days. Eight cases of VAP were reported over 
the same time period. VAP occurred in 0.39% of venti-
lated patients, with a rate of 0.40/1000 ventilator days. 
The proportion of patients and rates of VAP and positive 
BAL differed significantly (P < 0.001; Figure 1).
Discussion
This is the first report of BAL culture results in a large 
population of children on MV in whom BAL was the 
standard method to evaluate for ventilator-associated 
infection. While a positive BAL is usually considered to 
represent a bacterial respiratory infection, our data indi-
cate that many mechanically ventilated children acquire 
infections that do not meet the definition of VAP. The 
rate of positive BAL in our institution was comparable 
to the rate of VAT based on ETA cultures previously 
reported in similar PICU populations.6-8 The frequency 
of a positive culture from a BAL specimen (53%) also 
compares to a recent report by Willson et al, which 
showed 37% to 53% of ETA surveillance cultures 
beyond the third day of MV with a new sterile catheter 
were positive.3 These observations raise questions about 
the superiority of BAL over ETA, and of the specificity 
of either in diagnosing true infection. Differing micro-
biological methods may not improve the diagnosis of 
ventilator-associated infections.3
The retrospective analysis of our de-identified data-
base limited our ability to contextualize culture results 
with clinical symptoms. Because of this, it is uncertain if 
the positive cultures represent bacterial colonization or 
clinically significant infection. However, our method of 
obtaining cultures eliminates concerns for contamina-
tion by the endotracheal tube or inline catheter, and we 
only send cultures to evaluate for suspected infection 
and not for surveillance. Therefore, we assume positive 
BAL patients likely had a ventilator-associated infec-
tion. The rate may be underestimated if there was varia-
tion in practice in obtaining cultures in the presence of 
clinical symptoms. Because the database contained day 
of PICU admission but not day of initiation of MV, some 
cultures evaluated may have been taken during the first 
2 days of MV if this was initiated beyond the day of 
admission, leading to an overestimation.
There is a discrepancy between the numbers of VAP 
reported by hospitals, with many hospitals reporting a 
zero rate, and the numbers of patients treated clinically 
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for ventilator-associated infection.11 Our data support 
this discrepancy, which is largely due to subjectivity and 
interpretation of the surveillance definitions used. There 
was a recent change in surveillance definitions used in 
adult patients to various levels of “ventilator-associated 
events.”12 Although this new definition attempted to be 
more objective, there is still potential subjectivity in cat-
egorization of conditions based on practice variation in 
ventilation strategies and antimicrobial use. The sub-
jectivity in VAP definitions opens the possibility of 
“gaming the system” in which clinically significant 
ventilator-associated infections are not reported as VAP 
due to alterations in documentation of clinical signs, 
interpretation of chest radiograph findings, or manage-
ment of increased oxygen requirements.
Also, while VAP definitions are admittedly for sur-
veillance use only, they cannot guide clinical diagnosis 
and management. A focus on developing a standardized 
approach to prevention, diagnosis, and management 
of ventilator-associated infections across institutions is 
warranted to improve consistency of care. More study is 
needed to determine the role of subjective criteria of 
infection and “objective” microbiology data in such a 
guideline. A surveillance method integrated with man-
agement guidelines may be more effective at tracking 
actual rates of ventilator-associated infections. We 
believe that an algorithm that can be used both for 
monitoring and also for guidance on the diagnosis and 
management of ventilator-associated infections would 
go a long way toward standardizing practice and improv-
ing patient safety.
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Figure 1. Study design and main results.
Abbreviations: BAL, bronchoscopic or non-bronchoscopic bronchoalveolar lavage; VAP, ventilator-associated pneumonia.
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